Stockreport

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Dogwood Therapeutics, Inc.  (DWTX) 
PDF - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for [Read more]